Highlights
The PROMIT trial investigated a novel approach to overcome primary resistance to immune checkpoint inhibitors (ICIs) in patients with metastatic melanoma. Key highlights include:
- An overall objective response rate (ORR) of 18% following dacarbazine priming and ICI rechallenge.
- A disease control rate (DCR) of 37% in a patient population with previously progressive disease.
- The treatment was well-tolerated, with grade 3 or higher adverse events occurring in only 10% of participants.
- Evidence suggesting that short-term, intermittent alkylating chemotherapy may reset the tumor microenvironment for immunotherapy.
